# Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

> **NCT00896480** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Immunotherapeutic GSK2132231A

## Key facts

- **NCT ID:** NCT00896480
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-19
- **Primary completion:** 2014-11-03
- **Final completion:** 2014-11-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896480, "Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00896480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*